| abstract |
Methods are provided for administering recombinant human growth hormone GX-H9 for the treatment of growth hormone deficiency. In particular, the present disclosure relates to a pharmaceutical composition for the treatment of growth hormone deficiency, the pharmaceutical composition comprising recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, wherein the recombinant GX-H9 is administered once a week at a dose Administered at 0.1 mg/kg to 0.3 mg/kg patient body weight or twice monthly at doses of 0.1 mg/kg patient body weight to 0.4 mg/kg patient body weight. Furthermore, the present disclosure relates to a method of treating growth hormone deficiency, comprising administering to a patient with growth hormone deficiency recombinant hGH GX-H9 once a week at a dose of 0.1 mg/kg to 0.3 mg/kg of the patient's body weight, or every Twice a month, doses ranged from 0.1 mg/kg patient body weight to 0.4 mg/kg patient body weight. |